What is Theranostics?

Pluvicto for Metastatic Prostate Cancer

Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) is an outpatient treatment, administered intravenously. It is provided in six cycles of therapy, six weeks apart. Pluvicto concentrates within prostate tumors that express the prostate-specific membrane antigen (PSMA), harming or killing the cancer cells with radiation. Candidates for this therapy must undergo a PSMA PET scan that shows that their tumor(s) concentrate the PET agent, which would be an indication that they would also concentrate the corresponding radiotherapeutic. Pluvicto is well-tolerated, with few side effects, can provide relief from pain and may prolong life.

What Are the Benefits?

• Precise disease detection
• Targeted treatment delivery
• Tailored treatments according to individual patient needs
• Minimizes unnecessary treatments and reduces adverse effects

What to Expect

Your visit to TRA Medical Imaging promises a seamless and exceptional patient experience, reflecting our commitment to your well-being. From the moment you step through our doors, you can expect a warm and welcoming atmosphere where your comfort is our priority. Our compassionate team of healthcare professionals will guide you through every step of your journey, ensuring your questions and concerns are heard and addressed with utmost care.

Pluvicto therapy involves receiving 6 doses intravenously, 6 weeks apart (pending patient health), with diagnostic imaging between treatments. Due to the radioactivity of treatment we encourage patients to drive themselves, if possible. Patients can bring one caregiver; however, the caregiver may not be present during the delivery of the radiopharmaceutical.

Xofigo for Metastatic Prostate Cancer

Xofigo (radium-223 dichloride) is a radioactive therapeutic agent used for the treatment of metastatic prostate cancer, specifically castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Xofigo works by mimicking calcium and selectively targeting bone metastases. It emits alpha particles that cause double-strand breaks in DNA, leading to cell death in nearby cancer cells while minimizing damage to surrounding healthy tissue.

This treatment is indicated for patients whose prostate cancer has progressed despite androgen deprivation therapy and who exhibit symptomatic bone metastases. It is specifically used when the cancer has spread to bones, causing pain or other symptoms, and there is no evidence of cancer in other organs (visceral metastases).

What Are the Benefits?

• Reduces bone pain associated with metastases
• Targeted treatment delivery
• Potentially extend overall survival in patients with with metastatic CRPC

What to Expect

Your visit to TRA Medical Imaging promises a seamless and exceptional patient experience, reflecting our commitment to your well-being. From the moment you step through our doors, you can expect a warm and welcoming atmosphere where your comfort is our priority. Our compassionate team of healthcare professionals will guide you through every step of your journey, ensuring your questions and concerns are heard and addressed with utmost care.

Xofigo is administered via intravenous injection, typically given once every four weeks for a total of six injections, with interval diagnostic imaging between treatments. Due to the radioactivity of treatment we encourage patients to drive themselves, if possible. Patients can bring one caregiver; however, the caregiver may not be present during the delivery of the radiopharmaceutical.